--- title: "Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor" type: "News" locale: "en" url: "https://longbridge.com/en/news/278866506.md" description: "Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor" datetime: "2026-03-12T10:45:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278866506.md) - [en](https://longbridge.com/en/news/278866506.md) - [zh-HK](https://longbridge.com/zh-HK/news/278866506.md) --- # Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor ### Related Stocks - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [44080.HK](https://longbridge.com/en/quote/44080.HK.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) ## Related News & Research - [Sino Biopharmaceutical Enrolls First Patient in Heart Drug Study](https://longbridge.com/en/news/282276920.md) - [Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205](https://longbridge.com/en/news/282119054.md) - [Sino Biopharm Gets Launch Nod for Opioid-Induced Constipation Drug from Guangdong Regulator](https://longbridge.com/en/news/282175575.md) - [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md) - [Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial](https://longbridge.com/en/news/282675084.md)